The MycetOS (Mycetoma Open Source) project was launched today by the University of Sydney, Erasmus MC, and the Drugs for Neglected Diseases initiative (DNDi) to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.
neglected diseases
See the following -
Africa: Partners Commit To Bolster Open Source Research
Press Release |
Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), Royal Society of Chemistry (RSC) |
November 27, 2013
The Royal Society of Chemistry (RSC), UK, Drugs for Neglected Diseases initiative (DNDi) and MMV have signed a memorandum of understanding (MoU) to collaborate in an effort to build a global community of researchers contributing to open source drug discovery for diseases of poverty. Read More »
- Login to post comments
Less Neglect, More Openness: Two ‘Grand Experiments’ In Health Innovation
Bernard Pécoul | PLOS.org | November 28, 2013
Commemorating the 10th Anniversaries of PLOS and the Drugs for Neglected Diseases initiative (DNDi), Bernard Pécoul, Executive Director of DNDi, discusses the innovative journeys of the organisations. Read More »
- Login to post comments
Medicines Shouldn't Be A Luxury - Médecins Sans Frontières
Staff Writer | MSF Access | January 28, 2015
What if the medicines that could save your life cost a hundred times what you earn in a year? Many people in developing countries can’t get hold of the treatment they need to stay alive and healthy...
- Login to post comments
New Open Source Drug Discovery Project Aims to Develop Mycetoma Treatment
Press Release |
ErasmusMC , University of Sydney , DNDi |
February 6, 2018
- Login to post comments
Open Source Drug Discovery Test A Success
Press Release |
University Of Washington Health Sciences/UW Medicine |
July 28, 2016
In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer...One-third of the labs reported their results in a paper published today in PLOS Pathogens, "Open source drug discovery with the Malaria Box compound collection for neglected diseases and beyond." The results have ignited more a dozen drug-development projects for a variety of diseases. "The trial was successful not only in identifying compounds to pursue for anti-malarials, but it also identified compounds to treat other parasites and cancer," said lead author Wesley Van Voorhis.
- Login to post comments
Patient Engagement, Data Liberation And Portability
Christine Årdal and John-Arne Røttingen | PLOS Neglected Tropical Diseases | September 20, 2012
Open source drug discovery can be an influential model for discovering and developing new medicines and diagnostics for neglected diseases. It offers the opportunity to accelerate the discovery progress while keeping expenditures to a minimum by encouraging incremental contributions from volunteer scientists.
Read More »
- Login to post comments
PLOS & DNDi Launch A New Collection Celebrating A Decade Of Open Access And NTD R&D
Rhona MacDonald | PLOS.org | December 5, 2013
As part of a collaborative initiative, PLOS and the Drugs for Neglected Diseases initiative (DNDi) are delighted to launch a special Collection—PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D—to coincide with a joint event at the Institut Pasteur in Paris celebrating the 10 year anniversary of DNDi... Read More »
- Login to post comments
Copyright ©2011-2020 Open Health Marketplace, LLC. All Rights Reserved.